The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial
Abstract
Objective: To evaluate the long‐term efficacy and safety of etanercept in children with juvenile rheumatoid arthritis (JRA) participating in an ongoing multicenter, open‐label, extended‐treatment trial. All patients had been participants in an initial randomized efficacy and safety trial of etanercept. Methods: Etanercept was administered at a dosage of 0.4 mg/kg (maximum 25 mg) subcutaneously twice each week. Safety and efficacy evaluations were performed every 3–4 months. The JRA 30% definition of improvement (DOI) was defined as improvement of ≥30% in at least 3 of 6 response variables used to assess disease activity, with no more than 1 variable worsening by more than 30%. Results: At the time of analysis, 48 of the 58 patients (83%) were still enrolled in the study; 43 of them (74%) had completed 2 years of treatment. Of these 43 patients, 81% met the JRA 30% DOI, 79% met the JRA 50% DOI, and 67% met the JRA 70% DOI. Ten children started low‐dose methotrexate after year 1. Of the 32 children taking prednisone, the dosage was decreased to <5 mg/day in 26 (81%). Two children had serious infections (varicella with aseptic meningitis in one and complicated sepsis in the other). In general, adverse events were of the types seen in a general pediatric patient population. Conclusion: Children with severe, longstanding, methotrexate‐resistant polyarticular JRA demonstrated sustained clinical improvement with >2 years of continuous etanercept treatment. Etanercept was generally well‐tolerated. There were no increases in the rates of adverse events over time. However, children taking etanercept should be monitored closely for infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of health status in children with juvenile rheumatoid arthritis
Singh, G., Athreya, B. H., Fries, J. F., & Goldsmith, D. P. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371209 · Cited by 838
Cited by
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Davis, J. C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D. O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11325 · Cited by 754
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Ringold, S., Angeles‐Han, S. T., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., Colbert, R. A., Feldman, B. M., Ferguson, P. J., Gewanter, H., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23870 · Cited by 462
Self-citationInfection, fever, and exogenous and endogenous pyrogens: some concepts have changed
Dinarello, C. A. (2004) · Journal of Endotoxin Research · doi:10.1179/096805104225006129 · Cited by 435
Metadata
- Authors
- Lovell, D. J., Giannini, E. H., Reiff, A., Jones, O. Y., Schneider, R., Olson, J. C., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., Lange, M., Finck, B. K., Burge, D. J., & for the Pediatric Rheumatology Collaborative Study Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-01
- Volume
- 48
- Issue
- 1
- Pages
- 218-226
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2066546529
- Cited by
- 250
- References
- 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.